Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs Velvet Rx

REMEVi
Graded #70

Higher grade

vs+15.399999999999999
Velvet Rx
Graded #381

Lower grade

The verdict

REMEVi takes it — 73.5/100 to 58.1/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +15
57
42
Dose & formulationREMEVi +8
83
75
Clinical oversightREMEVi +19
86
67
Labs & monitoringREMEVi +2
55
53
FulfillmentREMEVi +40
97
57
Contract termsREMEVi +14
69
55
REMEVi · left barVelvet Rx · right bar

The numbers

MetricREMEViVelvet Rx
WeighScore73.5/10058.1/100
GradeCC
Scorecard rank#70#381
Semaglutide$219/mo$299/mo (compounded)
Tirzepatide$319/mo$359/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Velvet Rx

Graded #381 · C

Strengths

  • Public pricing across 3 SKUs (semaglutide $299, tirzepatide $359, oral GLP-1 $349) — uncommon in compounded telehealth
  • First-month promo pricing shown upfront ($139 sema / $199 tirz / $189 oral)
  • Single monthly price includes consult, prescription, 4 weeks of medication, and free 1–2 day shipping
  • FSA/HSA eligible
  • Three options under one roof: injectable sema, injectable tirz, and an oral GLP-1

Where it loses points

  • Oral GLP-1 SKU doesn't name the specific drug — a real gap given Rybelsus, Foundayo, and compounded oral semaglutide differ clinically
  • No LegitScript or NABP .pharmacy seal displayed
  • No legal entity name disclosed
  • No physical address disclosed
  • Compounding pharmacy partner not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard